Last reviewed · How we verify
Current Regimen
Repurposed to treat COVID-19 by inhibiting viral replication.
Repurposed to treat COVID-19 by inhibiting viral replication. Used for Treatment of COVID-19, Treatment of Ebola virus disease.
At a glance
| Generic name | Current Regimen |
|---|---|
| Also known as | Current HIV treatment regimen |
| Sponsor | University of Chicago |
| Drug class | Nucleoside analog |
| Target | RNA-dependent RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | FDA-approved |
Mechanism of action
Remdesivir works by targeting the viral RNA-dependent RNA polymerase, preventing the virus from replicating. This mechanism of action is effective against a broad range of RNA viruses, including SARS-CoV-2.
Approved indications
- Treatment of COVID-19
- Treatment of Ebola virus disease
Common side effects
- Increased liver enzymes
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Spot Analysis of Natriuresis to Guide up- or Down-titration of Diuretic Therapy in Ambulatory Patients With Chronic Heart Failure (NA)
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B (PHASE3)
- A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen (PHASE4)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Long-Term Safety Study Of Tofacitinib In Patients With Juvenile Idiopathic Arthritis (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |